Elena A. Mikhailova

Elena A. Mikhailova

Auto-generated profile, based on publicly available information

Elena A. Mikhailova

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
AAA. A. Abadjeva
A. A. Abadjeva
EME. A. Mikhailova
E. A. Mikhailova
MKM. A. Kulyov
M. A. Kulyov
YFYu. G. Fedukova
Yu. G. Fedukova
ЮФЮ. Г. Федюкова
Ю. Г. Федюкова
Currently, the use high doses chemotherapy (HDC) supported by autologous peripheral blood stem cells in consolidation is a necessary therapeutic option in patients with high-risk neuroblastoma (NB). Conditioning regimens and schemes of HDC remain the subject of debate. In recent years, the evidence base of the advantages of tandem myeloablative procedures in comparison with single-transplantation has been actively accumulated in clinical practice. This article presents our own experience of tandem-transplantation with stem cell rescue in the N.N. Petrov National Medical Research Centre of Oncology (Saint-Petersburg) in four patients with initially stratified high-risk group NB; two of them were NMYC amplified. Tandem consolidation included TC ([T]hiotepa, [C]yclophosphamide) and CEM ([C]arboplatin, [E]toposide, [M]elphalan) regimens. The acceptable toxicity of the tandem-transplantation is proved.

19 January 2025 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
NMN. V. Matinyan
N. V. Matinyan
Background. In the literature, information on the overexpression of disialoganglioside GD2 on the cells of malignant neoplasms is not uncommon. In this regard, this marker should be considered as a tumor-associated antigen, which may be a target on the cell surface in patients with poor prognosis.The aim of the study – improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated (unSA) and bone sarcomas) by incorporating targeted immunotherapeutic options (immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.Materials and methods. Ten patients with GD2-positive relapsed/refractory soft tissue sarcomas (STS, n = 4), osteosarcomas (OS, n = 2), Ewingʼs sarcomas (ES, n = 4) and unSA (n = 1) were included in the study. The gender ratio was 2.3:1 (boys:girls). The mean age at the time of inclusion in the study was 12 ± 2 years. The most of all patients (80 %) had a status of “primary resistant disease”. GD2 quantitative expression level was 29 ± 11 % (0.9 to 85 %). Patients were represented by deeply pretreated patients who received 8 to 25 cycles of 2+ line chemotherapy (mean 13). A total of 7 patients completed the full reinduction treatment (6 cycles of chemoimmunotherapy). All patients received anti-GD2 MA 100 mg/m2 as an intravenous 5-day infusion every 4 weeks, and treatment was continued until disease progression or 6 cycles. Fifty-two cycles of immunotherapy were performed.Results. Pain syndrome was the most frequently diagnosed (after 16 cycles, or in 30.7 % of cases); 5 (9.6 %) cycles each were accompanied by diarrhea, cytokine release syndrome, and increased capillary permeability syndrome. The immediate results varied according to the histological subtype of the tumor. The overall objective response rate was 43 % (3/7): 2 patients achieved complete remission (CR) and one achieved partial remission (PR). The disease control rate (CR + PR + stable) was 86 % (6/7). The clinical response rate 6 months after completion of chemoimmunotherapy ranged from 0 % (2/2) in ES to 50 % (1/2) in OS. In 43 % (3/7) of evaluable patients, disease progression was diagnosed after a mean of 5 months. At follow-up after 12 and 24 months, CR persisted in all patients with STS (100 %). Progression-free survival (PFS) in patients with STS at 6, 12 and 24 months was 100 % (PFS6, PFS12, PFS24, respectively). PFS6 in OS and ES patients was 100 % and 50 %, respectively, gradually decreasing to 0 %. The study revealed a very strong positive straight-line positive functional correlation between quantitative GD2 expression and progression-free survival (r = 0.971, p = 0.00006).Conclusion. Passive immunotherapy with monoclonal antibodies is a safe treatment method without severe immune-related adverse reactions. Patient follow-up and evaluation of the efficacy and safety of the drug after the end of the therapy plan continues until today, which allows a more detailed and objective evaluation of the results of immunotherapy according to the purpose of the study.

22 January 2020 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
NFN. D. Faseeva
N. D. Faseeva
SKS. A. Kuleva
S. A. Kuleva
SIS. V. Ivanova
S. V. Ivanova
EGE. D. Gumbatova
E. D. Gumbatova
ESE. M. Senchurov
E. M. Senchurov
KBK. M. Borokshinova
K. M. Borokshinova
Опыт применения пассивной иммунотерапии у пациентов с нейробластомой группы высокого риска

12 July 2021 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
ANA. K. Nosov
A. K. Nosov
SKS. A. Kuleva
S. A. Kuleva
SIS. V. Ivanova
S. V. Ivanova
ESE. M. Senchurov
E. M. Senchurov
RKR. I. Khabarova
R. I. Khabarova
AKA. V. Khokhlova
A. V. Khokhlova
The modern Wilms tumor treatment protocols used all over the world can cure up to 90 % of children. Such successes make it possible to actively introduce risk-adapted therapy methods aimed at de-escalating the chemotherapy regimen and radiation therapy impact to the tumor. The most conservative was the stage of surgical treatment, implying the organ-depleting nature of the surgery. Nevertheless, over the past decade, a lot of experience has been accumulated with both nephron-sparing and minimally invasive interventions in patients with both bilateral and unilateral Wilms tumor.We presented the experience of laparoscopic kidney resection with intraoperative ultrasound control in a child with unilateral Wilms tumor, receiving treatment at the N.N. Petrov National Medical Research Center of Oncology.

25 December 2025 in Supportive Therapy in Oncology
Verified
Journal Article
Open access
PDF file
AKAlika A. Kulyova
Alika A. Kulyova
SKSvetlana A. Kulyova
Svetlana A. Kulyova
RKRina I. Khabarova
Rina I. Khabarova
ESEvgeniy M. Senchurov
Evgeniy M. Senchurov
EMElena A. Mikhailova
Elena A. Mikhailova
TVTatiana L. Vershinina
Tatiana L. Vershinina
Immunotherapy is one of the most effective methods of cancer therapy. There are five main groups of immunotherapy, including treatment with chimeric antigen receptor T cells, checkpoint inhibitors, anticancer vaccines, antibody-based targeted therapies, and oncolytic viruses. On the adult cohort of patients, immunotherapy has been proven to increase the survival rate of patients with cancer. At the same time, in some patients, it can cause an immune-mediated damage and contribute to unfavorable heart immune modulation and heart failure. Immunotherapy can target many components of the cardiovascular system, including the myocardium, blood vessels, electrical wiring, and the pericardium. Activated T lymphocytes (CD4 + and CD8 + T cells) penetrate the heart tissue and skeletal targets, which leads to local inflammation and damage. Additional theoretical mechanisms for side effects include autoantibody recognition of self-antigens and T cell-mediated damage to cardiomyocytes and stressed endothelial cells. After treatment with T cells, the level of proinflammatory cytokines may increase, which is often the cause of cytokine release syndrome, the occurrence of which is considered a “targeted, non-neoplastic” effect. Proinflammatory cytokines can have negative cytotoxic effects on cardiomyocytes, resulting in reduced myocardial contractility, cardiomyopathy, and hypotension. This review presents a clinical case of cardiotoxicity due to the use of antiGD2 monoclonal antibodies in a child with a refractory form of osteosarcoma.

16 March 2026 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
SKSvetlana A. Kulyova
Svetlana A. Kulyova
OSOlga Savelieva
Olga Savelieva
IBIrina A. Baldueva
Irina A. Baldueva
KBKsenia M. Borokshinova
Ksenia M. Borokshinova
EMElena A. Mikhaylova
Elena A. Mikhaylova
НЛНехаева Татьяна Л.
Нехаева Татьяна Л.
Contacts: Svetlana Aleksandrovna Kulyova Kulevadoc@yandex.ru The immune system is able to destroy tumors, but the progression of the malignant process indicates a violation of this mechanism. Analysis of literature data on the prognostic effect of different microenvironment T subpopulations shows that cytotoxic CD8+-T cells and memory T cells associated with Th1-type immune response correlate with good clinical course in most cancer types studied. On the other hand, the prognostic value of Th2, Th17 or Treg cell populations is inconsistent and varies depending on the type and stage of malignancy. Overall, these results strongly suggest that tumor behavior should now be viewed as the result of a balance between an invasive tumor process and a coordinated macroorganism immune response. In children, the microenvironment of solid tumors is heterogeneous, dynamic, and distinct from the microenvironment of neoplasias found in adults. Due to the low mutation burden, tumors in children have a limited set of neoantigens that could be recognized, and a small number of infiltrating T cells are represented in their tumor environment. Traditional biopsy does not always reflect tumor heterogeneity, so the focus shifts to peripheral blood testing. Biomarkers in the blood allow reassessment at different time points, they are readily available and their sampling is less invasive for patients. In addition, they can provide more information on immune status and assist in assessing a patient’s potential to develop effective immunity against a tumor. The article presents a modern view of immunological landscape of malignant tumors with a complex network of various cell populations and interactions between them.